CIBC World Markets Inc. lessened its stake in Edwards Lifesciences Co. (NYSE:EW) by 21.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 60,202 shares of the medical research company’s stock after selling 16,764 shares during the quarter. CIBC World Markets Inc.’s holdings in Edwards Lifesciences were worth $5,492,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of EW. Jackson Square Partners LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter valued at about $480,262,000. UBS Asset Management Americas Inc. increased its position in Edwards Lifesciences by 10.0% during the third quarter. UBS Asset Management Americas Inc. now owns 5,757,837 shares of the medical research company’s stock worth $459,591,000 after buying an additional 524,179 shares during the last quarter. Fisher Asset Management LLC raised its stake in Edwards Lifesciences by 7.4% in the fourth quarter. Fisher Asset Management LLC now owns 5,578,633 shares of the medical research company’s stock valued at $508,939,000 after buying an additional 386,233 shares during the period. Wells Fargo & Company MN lifted its position in shares of Edwards Lifesciences by 1.8% in the third quarter. Wells Fargo & Company MN now owns 4,615,487 shares of the medical research company’s stock valued at $368,408,000 after buying an additional 81,391 shares during the last quarter. Finally, Ownership Capital B.V. increased its holdings in shares of Edwards Lifesciences by 25.1% during the 4th quarter. Ownership Capital B.V. now owns 4,127,939 shares of the medical research company’s stock worth $376,592,000 after acquiring an additional 828,870 shares during the last quarter. Institutional investors and hedge funds own 80.94% of the company’s stock.

In other news, VP Jean-Luc M. Lemercier sold 20,523 shares of the firm’s stock in a transaction on Monday, January 4th. The stock was sold at an average price of $91.24, for a total transaction of $1,872,518.52. Following the completion of the sale, the vice president now directly owns 152,241 shares of the company’s stock, valued at approximately $13,890,468.84. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Nicholas J. Valeriani sold 8,200 shares of the firm’s stock in a transaction on Thursday, February 4th. The shares were sold at an average price of $85.21, for a total value of $698,722.00. Following the sale, the director now directly owns 67,896 shares of the company’s stock, valued at $5,785,418.16. The disclosure for this sale can be found here. Insiders sold a total of 264,171 shares of company stock valued at $22,820,527 over the last three months. 1.48% of the stock is currently owned by insiders.

EW has been the topic of several research analyst reports. Credit Suisse Group increased their price objective on shares of Edwards Lifesciences from $97.00 to $111.00 in a research report on Monday, December 7th. SVB Leerink lifted their price target on Edwards Lifesciences from $100.00 to $106.00 and gave the stock an “outperform” rating in a report on Friday, December 11th. Jefferies Financial Group upped their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Tuesday, October 27th. Canaccord Genuity raised their price target on shares of Edwards Lifesciences from $89.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, December 11th. Finally, Raymond James raised their target price on shares of Edwards Lifesciences from $90.00 to $96.00 and gave the stock an “outperform” rating in a report on Friday, December 11th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the stock. Edwards Lifesciences currently has an average rating of “Hold” and an average target price of $91.45.

Shares of NYSE:EW opened at $83.34 on Tuesday. The company has a quick ratio of 2.61, a current ratio of 3.52 and a debt-to-equity ratio of 0.14. Edwards Lifesciences Co. has a twelve month low of $51.51 and a twelve month high of $92.08. The stock’s 50 day moving average is $86.53 and its 200-day moving average is $83.31. The firm has a market capitalization of $52.05 billion, a price-to-earnings ratio of 66.67, a PEG ratio of 2.61 and a beta of 0.97.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, January 26th. The medical research company reported $0.50 earnings per share for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.03). Edwards Lifesciences had a return on equity of 29.00% and a net margin of 18.18%. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same period in the previous year, the company earned $1.46 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 1.5% compared to the same quarter last year. Equities research analysts anticipate that Edwards Lifesciences Co. will post 1.89 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Further Reading: Conference Calls and Individual Investors

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.